Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery

NCT06500143 | Completed

• 1 other identifier: MP-12-2025-3794
• Study Type: observational
• Target: 94
• Locations: 1 country
• Sites: 1

Brief Summary

Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying. The goal of this study is to evaluate the effect of GLP-1RA on the effectiveness of fasting before a scheduled surgery. The question it aims to answer is: does this kind of medication increase the risk of having food or too much liquid in the stomach before a scheduled surgery, even if the minimum 6 hour fast is done? For this project, researchers will use gastric ultrasound to compare participants already taking one of these medications as part of their home treatment to participants who are not taking them. Gastric ultrasound is a simple bedside exam using an echography machine that takes less than 5 minutes to do. Participants will:

• Have a gastric ultrasound performed on them before their surgery

Conditions

Gastric Retention

Keywords

glucagon-like peptide 1; gastric ultrasound; surgery; diabetes; weight loss; increased residual gastric content; semaglutide; dulaglutide

Outcome Measures

Primary Outcomes (1)

• Increased residual gastric content

  The primary endpoint will be the prevalence of increased residual gastric content defined by the presence of any of the following: * Solid or thick fluid content on gastric ultrasound * Content of more than 1.5 mL/kg of clear fluids on gastric ultrasound using the following formula : Gastric volume (mL) = 27 + \[14.6 × right lateral cross-sectional area (in cm2)\] - \[1.28 × age (in years)\]

  Preoperative (day of surgery)

Study Arms (2)

GLP-1RA agonists users

Participants presenting for elective surgery and taking once-weekly semaglutide or dulaglutide as part of their usual treatment with the last dose at least 7 days before surgery

Diagnostic Test: Gastric ultrasound

Control group

Participants presenting for elective surgery and not taking semaglutide or dulaglutide

Diagnostic Test: Gastric ultrasound

Interventions

Gastric ultrasound DIAGNOSTIC_TEST

Using a curved array low-frequency abdominal probe (2-5 MHz) with abdominal presets and with the patient in right lateral decubitus position, the gastric antrum will be identified in a standardized plane at the level of the aorta. The stomach will be considered empty if the antrum appears flat or round with anterior and posterior walls collapsed. Normal gastric secretions and clear fluids have an anechoic or hypoechoic aspect on ultrasonography. Solid or thick fluids have a hyperechoic aspect and can create "ring-down" artifacts blurring gastric content, its posterior wall, the pancreas and the aorta. Following qualitative examination, quantitative assessment will be performed if there is presence of clear fluids. The cross-sectional area (CSA) of the antrum will be measured with three measurements to calculate a mean value.

Control group; GLP-1RA agonists users

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult population undergoing elective surgery

You may qualify if:

• American Society of Anesthesiologists (ASA) class 1-4 patients
• Age ≥ 18 years old
• Fasted state (2 hours for clear liquids, 6 hours for solids)
• Elective surgery
• Last dose of once-weekly semaglutide or dulaglutide 7 days or more before surgery (for GLP-1RA group)

You may not qualify if:

• Last dose of GLP-1RA less than 7 days before surgery
• Inability to lay on the right-side for ultrasound
• Pregnancy
• History of gastric surgery or large hiatal hernia

Sponsors & Collaborators

• Ciusss de L'Est de l'Île de Montréal: lead
• Institut de Cardiologie de Montréal: collaborator

Study Sites (1)

CIUSSS de l'Est de l'Ile de Montréal

Montreal, Quebec, H1T2M4, Canada

Location

MeSH Terms

Conditions

Diabetes Mellitus; Weight Loss

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Body Weight Changes; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Louis Morisson, MD, MSc

  CIUSS de l'Est de l'Île de Montréal

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2024
• First Posted: July 15, 2024
• Study Start: October 9, 2024
• Primary Completion: February 28, 2025
• Study Completion: February 28, 2025
• Last Updated: January 16, 2026

Record last verified: 2025-12

Locations

CA (1)